PROVENTION BIO, INC.
PRVB evidence brief
What we can confirm
What it means
What to watch
Prepared research question
What matters most for PRVB—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper Score
Based on 4 of 6 signals
Financial data as of Dec 31, 2022.
Tracking 6 pipeline candidates · 1 clinical trial · 1 FDA decision for PROVENTION BIO, INC..
Run PROVENTION BIO, INC. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available PROVENTION BIO, INC. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Score breakdownBased on 4 of 6 signals · derived from public data
60.9 months
D/E 0.94
Lead: Approved
6 candidates
No upcoming catalysts tracked
No insider transactions in the last 180 days
Runway
Pipeline
Regulatory
Financials
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
316
Total value held
$1.18B
| Holder | Shares | Value |
|---|---|---|
| blackrock, inc. | 14,673,861 | $162.1M |
| vanguard capital management llc | 12,119,252 | $133.9M |
| vanguard portfolio management llc | 8,398,571 | $92.8M |
| state street corp | 6,417,472 | $70.9M |
| geode capital management, llc | 3,758,123 | $41.5M |
| goldman sachs group inc | 3,573,304 | $39.5M |
| capital management corp /va | 2,689,543 | $29.7M |
| dimensional fund advisors lp | 2,331,315 | $25.8M |
| morgan stanley | 2,275,231 | $25.1M |
| charles schwab investment management inc | 2,160,613 | $23.9M |
Showing top 10 of 316 institutional holders of PROVENTION BIO, INC.. Open the full 13F history after sign-in.
Short Interest
as of May 22, 2026- % of float
- 0.0%
- Days to cover
- 0.0
- Shares short
- 12,012
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
PRVB short interestGovernance
Frequently asked questions
What is PROVENTION BIO, INC.'s lead drug candidate?
PROVENTION BIO, INC.'s most advanced tracked candidate is ordesekimab (Phase 2) for Gluten-free diet non-responsive celiac disease (NRCD).
Who is the CEO of PROVENTION BIO, INC.?
Mr. Kurtis James Wolf is the chief executive officer of PROVENTION BIO, INC. (PRVB).
Where is PROVENTION BIO, INC. headquartered?
PROVENTION BIO, INC. (PRVB) is headquartered in Shelton, CT, United States.
What therapeutic areas does PROVENTION BIO, INC. focus on?
PROVENTION BIO, INC. develops therapies across Oncology, Immunology, Metabolic.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.